Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape
Abdulrahman Katib/LinkedIn
Feb 1, 2026, 08:46

Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape

Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:

“Factor XI inhibitors are quickly becoming one of the most intensely studied drug classes in thrombosis medicine today.

What makes them so exciting is the possibility of achieving meaningful antithrombotic protection while preserving hemostasis — something we have been striving for in anticoagulation for decades.

That said, true clinical efficacy still needs to be firmly established in some of our highest-risk populations, particularly cancer-associated thrombosis (CAT), where thrombosis biology and bleeding risk coexist in a very delicate balance.

On a personal level, I was truly privileged to be part of the MAGNOLIA and ASTER trials.

Being involved in research at this stage — before results are known — is a unique experience. It reminds you that every future guideline, every future practice change, starts with patients, investigators, and teams working together to answer difficult clinical questions.

I am genuinely looking forward to seeing the final publications and understanding where Factor XI inhibition will ultimately position itself in our thrombosis treatment landscape.”

More posts about Abdulrahman Katib.

Abdulrahman Katib ASTER trials Cancer Associated Thrombosis Factor XI Inhibitors Health Hematology Hemostasis Hemostasis Today MAGNOLIA Trial Medicine thrombosis
NewsFeed